FY2016 Earnings Estimate for Depomed Inc. Issued By Roth Capital (DEPO)
Depomed Inc. (NASDAQ:DEPO) – Research analysts at Roth Capital cut their FY2016 earnings per share (EPS) estimates for shares of Depomed in a research report issued on Monday. Roth Capital analyst S. Henry now forecasts that the firm will post earnings of ($0.81) per share for the year, down from their previous forecast of ($0.76). Roth Capital currently has a “Buy” rating and a $28.00 target price on the stock. Roth Capital also issued estimates for Depomed’s Q4 2016 earnings at ($0.07) EPS, Q1 2017 earnings at ($0.03) EPS, Q4 2017 earnings at $0.11 EPS and FY2018 earnings at $0.79 EPS.
Several other brokerages also recently commented on DEPO. Mizuho reiterated a “hold” rating and set a $27.00 price target on shares of Depomed in a report on Tuesday, November 8th. Piper Jaffray Cos. downgraded Depomed from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $21.00 to $18.00 in a report on Wednesday, July 27th. Janney Montgomery Scott reiterated a “buy” rating and set a $31.00 price target on shares of Depomed in a report on Monday, October 17th. JMP Securities lowered their price target on Depomed from $28.00 to $22.00 and set a “market outperform” rating on the stock in a report on Thursday, August 4th. Finally, Leerink Swann reissued a “buy” rating on shares of Depomed in a research report on Sunday, October 2nd. One analyst has rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $23.06.
Depomed (NASDAQ:DEPO) traded up 0.50% during mid-day trading on Wednesday, reaching $20.24. 381,225 shares of the company’s stock traded hands. The stock’s market capitalization is $1.25 billion. Depomed has a 12 month low of $12.25 and a 12 month high of $27.02. The firm’s 50-day moving average price is $22.80 and its 200 day moving average price is $21.05.
Depomed (NASDAQ:DEPO) last released its earnings results on Monday, November 7th. The specialty pharmaceutical company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.35 by $0.07. Depomed had a negative net margin of 16.93% and a negative return on equity of 7.49%. The business had revenue of $111 million for the quarter, compared to the consensus estimate of $127.22 million. During the same quarter in the previous year, the firm earned $0.33 EPS. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis.
Hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC acquired a new stake in shares of Depomed during the third quarter worth $120,000. BlackRock Inc. raised its stake in shares of Depomed by 197.5% in the second quarter. BlackRock Inc. now owns 5,137 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 3,410 shares during the period. PineBridge Investments L.P. raised its stake in shares of Depomed by 4.1% in the second quarter. PineBridge Investments L.P. now owns 7,748 shares of the specialty pharmaceutical company’s stock worth $152,000 after buying an additional 306 shares during the period. DIAM Co. Ltd. acquired a new stake in shares of Depomed during the second quarter worth $157,000. Finally, Teacher Retirement System of Texas raised its stake in shares of Depomed by 13.7% in the second quarter. Teacher Retirement System of Texas now owns 8,482 shares of the specialty pharmaceutical company’s stock worth $166,000 after buying an additional 1,024 shares during the period.
In other news, VP Thadd M. Vargas sold 11,250 shares of the firm’s stock in a transaction on Wednesday, September 21st. The stock was sold at an average price of $25.00, for a total value of $281,250.00. Following the completion of the sale, the vice president now directly owns 73,086 shares in the company, valued at $1,827,150. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO August J. Moretti sold 5,000 shares of the firm’s stock in a transaction on Monday, November 14th. The shares were sold at an average price of $20.84, for a total value of $104,200.00. Following the completion of the sale, the chief financial officer now owns 26,680 shares of the company’s stock, valued at $556,011.20. The disclosure for this sale can be found here. Company insiders own 5.12% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “FY2016 Earnings Estimate for Depomed Inc. Issued By Roth Capital (DEPO)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2016/11/23/fy2016-earnings-estimate-for-depomed-inc-issued-by-roth-capital-depo.html.
Depomed Company Profile
Receive News & Stock Ratings for Depomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc. and related stocks with our FREE daily email newsletter.